Dr Karin Hellner
Biography & Research
I received my medical degree from the Humboldt-University of Berlin in 2003 and split my specialist training in Obstetrics & Gynaecology between the Charité - Universitätsmedizin Berlin, in Germany, and Oxford.
I spent 4 years as a postdoctoral research fellow at Harvard Medical School / Brigham & Women's Hospital in Boston, USA, where I have been working on the molecular mechanisms of human papillomavirus (HPV) associated carcinogenesis and drug discovery strategies for cervical cancer.
I joined the University of Oxford in 2011 as a Clinical Lecturer and was appointed as Senior Fellow in Women's Health in 2017.
I have a strong clinical interest in HPV associated cervical disease and am leading a research program in the field of the molecular basis and clinical management of cervical dysplasia. I am the lead consultant for Oxford's colposcopy service and Principal Investigator of multiple national and international clinical trials.
In addition, I am a board member of the British Society for Colposcopy and Cervical Pathology (BSCCP) representing the South-East of England, a BSCCP accredited colposcopy trainer and elected member of the Society for Reproductive Investigation (SRI). In my spare time I volunteer as expert reviewer for Jo's Cervical Cancer Trust Charity.
For colposcopy related queries please contact my NHS secretary Ms Charlotte Whipp on 01865572110 or firstname.lastname@example.org.
For private patient referrals please contact my PP secretary Ms Janet White at email@example.com.
Senior Fellow in Women's Health
- Group Leader
- Consultant Gynaecologist and Colposcopist at Oxford University Hospitals NHS Foundation Trust
- Clinical Lead for Colposcopy
- Chief-Investigator for HPV001 (Therapeutic HPV Vaccine)
- BSCCP Representative for South-East England
My research focusses on high-risk HPV and strategies to eradicate HPV associated (pre)-cancers
We are carrying out a number of research studies to help us design and test new treatments for cervical abnormalities caused by infection with oncogenic HPV.
Therapeutic HPV Vaccine
HPV001 is investigating the broadest therapeutic vaccine to show efficacy against cervical abnormalities associated with 5 of the most common high-risk HPV types and is a randomised, double-blind, placebo-controlled study involving trial sites across the UK and Europe. Oxford is the lead trial site and we are now open for recruitment. Read more about the study in The Guardian. If you are interested, please contact the research team on firstname.lastname@example.org.
HPV Immunity study
This trial aims to find out how the immune system clears high-risk HPV, the viruses that cause cervical cancer (http://www.jenner.ac.uk/hpv). The study has been looking at HPV induced immunity and clearance in healthy women aged 16-55 years and women with a history of persistent HPV and cervical lesions.
- Dr Gemma Hancock (Senior Postdoc in Reproductive Immunology)
- Lisa Buck (Research Midwife & Study Coordinator)
- Dr Maria Isabella Sereni (Consultant Gynaecologist & Sub-Investigator HPV001)
- Tabitha Wishlade (Research Midwife)
- Angelika Capp (Research Midwife)
Therapeutic HPV vaccines
Hancock G. et al, (2018), Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 59 - 72
Recent advances in understanding and preventing human papillomavirus-related disease
Hellner K. and Dorrell L., (2017), F1000Research, 6, 269 - 269
Human Papillomaviruses As Therapeutic Targets in Human Cancer
Hellner K. and Münger K., (2011), Journal of Clinical Oncology, 29, 1785 - 1794
A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins
DORRELL L. et al, (2019), Scientific Reports
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation
Zheng Y. et al, (2018), Nature Communications, 9